FDA approves new treatment for seasonal allergic rhinitis
The FDA has approved azelastine HCI and fluticasone propionate nasal spray (Dymista, Meda) to treat seasonal allergic rhinitis.
The approval comes after several clinical studies involving more than 4,000 patients, demonstrated the drug's safety and efficacy, including one long-term safety study with more than 600 participants. Study results showed that azelastine HCI and fluticasone propionate nasal spray provided rapid and more complete symptomatic relief than standard treatment.
The combination nasal spray formulation is indicated for patients aged 12 years and older with seasonal allergic rhinitis and is expected to be available in the United States during the second half of 2012.
For more information call (732) 564-2200 or visit www.medapharma.us.